These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15780889)

  • 1. A SAS/IML program for simulating pharmacokinetic data.
    Russek-Cohen E; Martinez MN; Nevius AB
    Comput Methods Programs Biomed; 2005 Apr; 78(1):39-60. PubMed ID: 15780889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposal for a standardised identification of the mono-exponential terminal phase for orally administered drugs.
    Scheerans C; Derendorf H; Kloft C
    Biopharm Drug Dispos; 2008 Apr; 29(3):145-57. PubMed ID: 18098336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current challenges facing the determination of product bioequivalence in veterinary medicine.
    Martinez MN; Hunter RP
    J Vet Pharmacol Ther; 2010 Oct; 33(5):418-33. PubMed ID: 20840385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating product bioequivalence for highly variable veterinary drugs.
    Claxton R; Cook J; Endrenyi L; Lucas A; Martinez MN; Sutton SC
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():11-6. PubMed ID: 22413787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstrating bioequivalence using clinical endpoint studies.
    Bermingham E; Del Castillo JR; Lainesse C; Pasloske K; Radecki S
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():31-7. PubMed ID: 22413789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for extrapolating in vivo bioequivalence data across species and routes.
    Modric S; Bermingham E; Heit M; Lainesse C; Thompson C
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():45-52. PubMed ID: 22413791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination.
    Lees P; Hunter RP; Reeves PT; Toutain PL
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():17-29. PubMed ID: 22413788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 2010 AAVPT/EAVPT/ECVPT bioequivalence workshop.
    Martinez M; Hunter RP; Baynes R; Bermingham E; Claxton R; Cole C; Del Castillo J; Gehring R; Harshman K; Lainesse C; Lucas A; Modric S; Robinson J
    J Vet Pharmacol Ther; 2011 Apr; 34(2):105-7. PubMed ID: 21395599
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges associated with the evaluation of veterinary product bioequivalence: an AAVPT perspective.
    Martinez M; Langston C; Martin T; Conner D
    J Vet Pharmacol Ther; 2002 Jun; 25(3):201-20. PubMed ID: 12081616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
    Jaki T; Wolfsegger MJ; Ploner M
    Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of pharmacokinetics in veterinary drug residues.
    Lees P; Toutain PL
    Drug Test Anal; 2012 Aug; 4 Suppl 1():34-9. PubMed ID: 22851359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of bioequivalence study regulatory requirements for human and veterinary drugs.
    Grabowski T; Marczak M; Jaroszewski JJ; Whitmire M
    Regul Toxicol Pharmacol; 2012 Nov; 64(2):233-42. PubMed ID: 22917973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges associated with the demonstration of bioequivalence of intramammary products in ruminants.
    Lainesse C; Gehring R; Pasloske K; Smith G; Soback S; Wagner S; Whittem T
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():65-79. PubMed ID: 22413793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence accomplishments, ongoing initiatives, and remaining challenges.
    Martinez MN
    J Vet Pharmacol Ther; 2014 Feb; 37(1):2-12. PubMed ID: 23841644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective use of modeling and simulation in designing bioequivalence and comparability studies of large-molecule compounds: the case of erythropoietin.
    Nakai K; Miyata K; Iida S; Kawanishi T
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):488-98. PubMed ID: 25907174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient variation in veterinary medicine--part II--influence of physiological variables.
    Modric S; Martinez M
    J Vet Pharmacol Ther; 2011 Jun; 34(3):209-23. PubMed ID: 21083665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.